211 related articles for article (PubMed ID: 24757092)
1. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
2. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
[TBL] [Abstract][Full Text] [Related]
3. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
Todaro J; Bollmann PW; Rother ET; del Giglio A
Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
[TBL] [Abstract][Full Text] [Related]
5. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
[TBL] [Abstract][Full Text] [Related]
6. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
8. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.
Zhou Q; Hu Y; Howard OM; Oppenheim JJ; Chen X
Cytokine; 2014 Jan; 65(1):56-64. PubMed ID: 24080164
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
Goodyear OC; Dennis M; Jilani NY; Loke J; Siddique S; Ryan G; Nunnick J; Khanum R; Raghavan M; Cook M; Snowden JA; Griffiths M; Russell N; Yin J; Crawley C; Cook G; Vyas P; Moss P; Malladi R; Craddock CF
Blood; 2012 Apr; 119(14):3361-9. PubMed ID: 22234690
[TBL] [Abstract][Full Text] [Related]
10. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
12. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
Pollyea DA; Kohrt HE; Gallegos L; Figueroa ME; Abdel-Wahab O; Zhang B; Bhattacharya S; Zehnder J; Liedtke M; Gotlib JR; Coutre S; Berube C; Melnick A; Levine R; Mitchell BS; Medeiros BC
Leukemia; 2012 May; 26(5):893-901. PubMed ID: 22033493
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
[No Abstract] [Full Text] [Related]
16. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
18. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts.
Tao Q; Pan Y; Wang Y; Wang H; Xiong S; Li Q; Wang J; Tao L; Wang Z; Wu F; Zhang R; Zhai Z
Int J Cancer; 2015 Nov; 137(10):2384-93. PubMed ID: 25866142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
